<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17278" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>African Trypanosomiasis (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dunn</surname>
            <given-names>Noel</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wang</surname>
            <given-names>Sicong</given-names>
          </name>
          <aff>Madigan Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adigun</surname>
            <given-names>Rotimi</given-names>
          </name>
          <aff>Touro University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noel Dunn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sicong Wang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rotimi Adigun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17278.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>African trypanosomiasis, also known as human African&#x000a0;trypanosomiasis (HAT) and sleeping sickness, is caused by 1 of 2 <italic toggle="yes">Trypanosoma </italic><italic toggle="yes">brucei</italic> protozoa transmitted by the tsetse fly in sub-Saharan Africa. The disease is considered a neglected tropical disease and remains a nearly universal fatal disease if not treated.<xref ref-type="bibr" rid="article-17278.r1">[1]</xref><xref ref-type="bibr" rid="article-17278.r2">[2]</xref><xref ref-type="bibr" rid="article-17278.r3">[3]</xref></p>
      </sec>
      <sec id="article-17278.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Trypanosoma brucei</italic> is usually transmitted to humans from an infected tsetse fly.<xref ref-type="bibr" rid="article-17278.r4">[4]</xref></p>
      </sec>
      <sec id="article-17278.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>HAT<italic toggle="yes">&#x000a0;</italic><italic toggle="yes">Trypanosoma brucei gambiense</italic>&#x000a0;is a disease endemic to western sub-Saharan Africa, while HAT <italic toggle="yes">Trypanosoma brucei rhodesiense</italic> affects&#x000a0;areas of eastern sub-Saharan Africa. As the 2 diseases are spread by different tsetse subspecies, the 2 diseases do not overlap, though Uganda has both variants within its borders. Estimates of the disease prevalence have proven to be difficult, though some studies estimate 20,000 individuals are affected by the disease, with nearly 9100 dying from both variants in 2010.</p>
        <p>African trypanosomiasis can occur at any age and can affect all races.<xref ref-type="bibr" rid="article-17278.r5">[5]</xref></p>
      </sec>
      <sec id="article-17278.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Once the tsetse fly ingests the trypanosomes, they multiply and develop into epimastigotes. Humans are infected after the bite from a tsetse fly. The injected parasites then rapidly divide in the bloodstream and lymphatics. Eventually, the parasite enters the central nervous system (CNS) and causes neurological and behavioral symptoms.</p>
        <p>The trypanosomes evade the host's immune system because of extensive antigenic variation of the glycoproteins located&#x000a0;on the surface of the parasite. During this time, the parasites invade almost every organ in the body.</p>
        <p>Some individuals may develop a severe hypersensitivity reaction to the parasite that leads to itching, swelling, and edema.</p>
        <p>In the liver, there may be portal infiltration and fatty degeneration.</p>
        <p>When the heart is invaded, arrhythmias may develop leading to death.</p>
        <p>When the brain is involved, it may lead to meningoencephalitis, bleeding, edema, and granulomatous lesions.</p>
      </sec>
      <sec id="article-17278.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>HAT<italic toggle="yes">&#x000a0;</italic><italic toggle="yes">Trypanosoma brucei gambiense</italic></bold>
</p>
        <p>The initial stage often presents with a painless eschar at the point of infection, though this is often not recalled due to a prolonged asymptomatic course. Patients often have an indolent&#x000a0;first stage marked by posterior cervical lymphadenopathy (Winterbottom&#x02019;s sign), headaches, malaise, and arthralgias. As the disease progresses to the&#x000a0;second stage, patients will develop somnolence, fatigue, neurological deficits, tremors, ataxia, seizures, comas, and eventually death.</p>
        <p>
<bold>HAT <italic toggle="yes">Trypanosoma brucei rhodesiense</italic></bold>
</p>
        <p>Affected individuals typically present after inoculation with a painful eschar and a rapidly progressing illness marked by fevers, rash, fatigue, and myalgias. Within a few weeks to months, the disease progresses to the&#x000a0;second stage, with symptoms identical to that of HAT <italic toggle="yes">Trypanosoma brucei gambiense</italic>&#x000a0;but with a much-accelerated course that quickly leads to death.</p>
        <p>
<italic toggle="yes">
<bold>Physical Findings</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Induration at the bite site</p>
          </list-item>
          <list-item>
            <p>In light-skinned individuals, one may see skin lesions (trypanids)</p>
          </list-item>
          <list-item>
            <p>Generalized lymphadenopathy which is most prominent in the axilla and inguinal area.</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Splenomegaly</p>
          </list-item>
          <list-item>
            <p>Disorientation and altered mental status</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Stupor and coma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17278.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>HAT&#x000a0;<italic toggle="yes">Trypanosoma brucei gambiense</italic>&#x000a0;can be screened for with the card agglutination trypanosoma test (CATT), a study that examines serum for antigen and that carries a sensitivity of 91% and specificity of 97%. Both species can also be identified with Giemsa-stained blood, lymph node aspirates, and cerebrospinal fluid (CSF) fluid. All patients with suspected HAT should be screened for CNS involvement with a lumbar puncture; CSF fluid should be tested for trypanosomes, leukocytosis, and trypanosome IgM.&#x000a0; In the second-stage infections, the number of parasites in congestive heart failure (CHF) can be very&#x000a0;low. World Health Organization (WHO) diagnostic criteria for suspected second&#x000a0;stage trypanosomiasis, therefore, consists of either the presence of&#x000a0;trypanosomes in CSF fluid or greater than 5 white blood cells (WBCs) per microliter of fluid in a suspected case.</p>
        <p>In many hospitals, in Africa, a blood smear is often done as it will reveal the mobile trypanosomes. Blood smears are often positive in early disease when the number of circulating parasites is very&#x000a0;high.</p>
        <p>Lymph node aspiration is sometimes done to identify the parasite and may yield positive results.</p>
        <p>CT scan and MRI of the brain frequently reveal massive cerebral edema and enhancement of the white matter.</p>
      </sec>
      <sec id="article-17278.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The early stage management requires treatment of fever and malaise. Close monitoring of the CNS status is necessary. Sometimes, patients may require intubation and mechanical ventilation as they can not maintain a patent airway.<xref ref-type="bibr" rid="article-17278.r6">[6]</xref><xref ref-type="bibr" rid="article-17278.r7">[7]</xref><xref ref-type="bibr" rid="article-17278.r8">[8]</xref></p>
        <p>HAT&#x000a0;<italic toggle="yes">Trypanosoma brucei gambiense</italic>: Treatment during the first stage consists of pentamidine. After patients develop CNS symptoms, patients will require eflornithine and nifurtimox. If no response is achieved, providers may resort to melarsoprol.</p>
        <p>HAT&#x000a0;<italic toggle="yes">Trypanosoma brucei rhodesiense</italic>: Treatment of the initial stage consists of suramin while treatment of the&#x000a0;second stage consists of melarsoprol.</p>
        <p>Most studies today show that combination therapy with melarsoprol and nifurtimox is more effective than either solo therapy.</p>
      </sec>
      <sec id="article-17278.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Amebic meningoencephalitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Aspiration syndromes</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchiectasis imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Constipation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Constrictive pericarditis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Encopresis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intestinal malrotation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intestinal volvulus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intussusception</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leishmaniosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17278.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>If the infection is treated during the early stage, recovery is possible in most patients. However, if the patient presents with stage 2 disease, the CNS involvement usually is fatal. Today, the cure rate with the drug melarsoprol is more than 90%.<xref ref-type="bibr" rid="article-17278.r9">[9]</xref></p>
      </sec>
      <sec id="article-17278.s10" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Severe wasting</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Stupor</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonitis</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17278.s11" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <list list-type="bullet">
          <list-item>
            <p>Patients need long-term monitoring to ensure they have not developed any complications.</p>
          </list-item>
          <list-item>
            <p>The patients should be followed up with regular blood smears and lumbar puncture every three months for the first 12 months and then at six monthly intervals.</p>
          </list-item>
          <list-item>
            <p>If relapse is noted, then repeat treatment with melarsoprol is needed.</p>
          </list-item>
          <list-item>
            <p>Side effects of melarsoprol include hypertension, encephalopathy, neuropathy, cardiac damage, and vomiting.</p>
          </list-item>
          <list-item>
            <p>Side effects of suramin include emesis, neuropathy, kidney damage and blood dyscrasias.</p>
          </list-item>
          <list-item>
            <p>Side effects of eflornithine include pancytopenia, seizures, and hearing impairment.</p>
          </list-item>
          <list-item>
            <p>Because of these severe side effects, patients need to be closely monitored&#x000a0;and the dose adjusted or discontinued.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17278.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>If a patient is suspected of having African trypanosomiasis, immediate consultation with an infectious disease expert is recommended.</p>
        <p>If the patient is in the United States, one should contact the Centers for Disease Control and Prevention (CDC).</p>
      </sec>
      <sec id="article-17278.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>There is no vaccine yet available.</p>
          </list-item>
          <list-item>
            <p>Tourists should avoid travel to endemic areas and avoid wearing dark contrasting colors.</p>
          </list-item>
          <list-item>
            <p>The tsetse fly is not affected by any insect repellant.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17278.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Melarsoprol is an arsenical compound that must be administered in propylene glycol. Administration of the drug is painful and carries multiple adverse effects, the most serious consisting of the melarsoprol-induced encephalopathic syndrome.&#x000a0;This occurs in 1.5% to 28% of treatments and results in nearly a 50% mortality rate. All patients receiving the medication should, therefore, be monitored in a hospital setting.</p>
      </sec>
      <sec id="article-17278.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>African trypanosomiasis, also known as human African&#x000a0;trypanosomiasis (HAT) and sleeping sickness,&#x000a0;is caused&#x000a0;by 1 of 2&#x000a0;<italic toggle="yes">Trypanosoma&#x000a0;</italic><italic toggle="yes">brucei</italic>&#x000a0;protozoa transmitted by the tsetse fly in sub-Saharan Africa.&#x000a0;The disease is considered&#x000a0;a neglected tropical disease and remains a nearly universal fatal disease if not treated. However, most healthcare workers in North America are unlikely to see a case in their lifetime. But it is still important to consider this disorder in the differential in a patient coming from the tropics. The best advice is to immediately consult with infectious disease on how to make the diagnosis and manage the patient.</p>
      </sec>
      <sec id="article-17278.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17278&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17278">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17278/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17278">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17278.s17">
        <fig id="article-17278.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Vectors and organism of trypanosomiasis Left: Attributed To: This image was contributed by the International Atomic Energy Agency - International Atomic Energy Agency This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license. https://commons.wikimedia.org/wiki/Category:Glossinidae#/media/File:Tsetse-BKF-2.jpg
Middle: Curtis-Robles et al. [CC BY 4.0 (https://creativecommons.org/licenses/by/4.0)]
Right: 
Imported case in an American who brought it back from a hunting trip in Gambia. Photo by Margaret Uthman, MD. Pathological and histological images courtesy of Ed Uthman at flickr.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Trypanosomiasis__and__vectors" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17278.s18">
        <title>References</title>
        <ref id="article-17278.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franco</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cecchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Priotto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diarra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grout</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simarro</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Argaw</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Monitoring the elimination of human African trypanosomiasis: Update to 2016.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>e0006890</fpage>
            <pub-id pub-id-type="pmid">30521525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>e0006925</fpage>
            <pub-id pub-id-type="pmid">30521522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentley</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jamabo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boshoff</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Hsp70/J-protein machinery of the African trypanosome, Trypanosoma brucei.</article-title>
            <source>Cell Stress Chaperones</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-148</page-range>
            <pub-id pub-id-type="pmid">30506377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saarman</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Opiro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hyseni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Echodu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Opiyo</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dion</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aksoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caccone</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The population genomics of multiple tsetse fly (Glossina fuscipes fuscipes) admixture zones in Uganda.</article-title>
            <source>Mol Ecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-85</page-range>
            <pub-id pub-id-type="pmid">30471158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kame-Ngasse</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Njiokou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melachio-Tanekou</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Farikou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Simo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geiger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of symbionts and trypanosome infections in tsetse flies of two villages of the "Faro and D&#x000e9;o" division of the Adamawa region of Cameroon.</article-title>
            <source>BMC Microbiol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>23</day>
            <volume>18</volume>
            <issue>Suppl 1</issue>
            <fpage>159</fpage>
            <pub-id pub-id-type="pmid">30470177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Erath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tanghe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leed</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mensa-Wilmot</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sciotti</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gillingwater</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pollastri</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Anilinoquinoline based inhibitors of trypanosomatid proliferation.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e0006834</fpage>
            <pub-id pub-id-type="pmid">30475800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merritt</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Tediosi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for <italic>Trypanosoma brucei gambiense</italic>.</article-title>
            <source>Public Health Ethics</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-292</page-range>
            <pub-id pub-id-type="pmid">30429873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarawneh</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Al-Momani</surname>
                <given-names>LAA</given-names>
              </name>
              <name>
                <surname>Le&#x000f3;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gadetskaya</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Abu-Orabi</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tekwani</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Triazole and Isoxazole Derivatives as Potential Anti-infective Agents.</article-title>
            <source>Med Chem Res</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>1269</fpage>
            <page-range>1269-1275</page-range>
            <pub-id pub-id-type="pmid">30374214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17278.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazumba</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kaka</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ngoyi</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tshala-Katumbay</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e0006504</fpage>
            <pub-id pub-id-type="pmid">29897919</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
